Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor

Ren Fail. 2020 Nov;42(1):860-864. doi: 10.1080/0886022X.2020.1803087.

Authors

Huifang Zhang¹, Zineng Huang¹, Liyu He¹, Fang Yuan¹, Lin Sun¹, Fuyou Liu¹, Li Xiao¹

Affiliation

¹ Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia, Refractory / drug therapy*
Anemia, Refractory / pathology
Autoantibodies / blood*
Bone Marrow / pathology
Erythropoietin / adverse effects
Erythropoietin / immunology*
Female
Glycine / administration & dosage
Glycine / analogs & derivatives*
Humans
Hypoxia-Inducible Factor-Proline Dioxygenases / administration & dosage*
Isoquinolines / administration & dosage*
Middle Aged
Renal Insufficiency, Chronic / complications
Treatment Outcome

Substances

Autoantibodies
Isoquinolines
Erythropoietin
Hypoxia-Inducible Factor-Proline Dioxygenases
Glycine
roxadustat

Grants and funding

This work was supported by the National Natural Science Foundation of China [81570658].